Pacer Advisors Inc. Purchases 2,472,983 Shares of Progyny, Inc. (NASDAQ:PGNY)

Pacer Advisors Inc. grew its holdings in Progyny, Inc. (NASDAQ:PGNY - Free Report) by 12,579.4% in the 3rd quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 2,492,642 shares of the company's stock after acquiring an additional 2,472,983 shares during the period. Pacer Advisors Inc. owned 2.76% of Progyny worth $41,777,000 as of its most recent SEC filing.

Several other hedge funds also recently modified their holdings of PGNY. Quarry LP increased its position in Progyny by 1,900.0% during the second quarter. Quarry LP now owns 880 shares of the company's stock worth $25,000 after buying an additional 836 shares during the last quarter. Point72 Asia Singapore Pte. Ltd. bought a new stake in shares of Progyny during the 2nd quarter worth about $44,000. Cambridge Trust Co. acquired a new position in shares of Progyny during the 1st quarter valued at about $95,000. Mendota Financial Group LLC bought a new position in shares of Progyny in the 3rd quarter valued at approximately $56,000. Finally, 1620 Investment Advisors Inc. bought a new stake in Progyny during the second quarter worth approximately $97,000. Institutional investors and hedge funds own 94.93% of the company's stock.

Analyst Upgrades and Downgrades

PGNY has been the topic of several analyst reports. Leerink Partners dropped their price target on shares of Progyny from $25.00 to $21.00 and set a "market perform" rating on the stock in a research report on Thursday, September 19th. Canaccord Genuity Group downgraded shares of Progyny from a "buy" rating to a "hold" rating and dropped their target price for the stock from $37.00 to $24.00 in a report on Wednesday, August 7th. Cantor Fitzgerald restated an "overweight" rating and set a $25.00 price target on shares of Progyny in a report on Tuesday, October 1st. Barclays dropped their price objective on Progyny from $30.00 to $17.00 and set an "overweight" rating on the stock in a research note on Thursday, November 14th. Finally, JMP Securities downgraded Progyny from an "outperform" rating to a "market perform" rating in a research note on Thursday, September 19th. Eight research analysts have rated the stock with a hold rating and five have issued a buy rating to the company's stock. According to MarketBeat.com, Progyny presently has an average rating of "Hold" and an average price target of $25.42.

Progyny Trading Up 3.1 %

PGNY stock traded up $0.47 during midday trading on Friday, hitting $15.44. The stock had a trading volume of 1,381,553 shares, compared to its average volume of 1,403,383. The firm has a market capitalization of $1.31 billion, a price-to-earnings ratio of 26.62, a P/E/G ratio of 1.65 and a beta of 1.44. The stock has a 50-day simple moving average of $16.40 and a 200 day simple moving average of $22.74. Progyny, Inc. has a 52 week low of $13.39 and a 52 week high of $42.08.

Progyny (NASDAQ:PGNY - Get Free Report) last issued its earnings results on Tuesday, November 12th. The company reported $0.11 earnings per share for the quarter, missing the consensus estimate of $0.37 by ($0.26). The business had revenue of $286.63 million for the quarter, compared to analyst estimates of $296.85 million. Progyny had a net margin of 5.03% and a return on equity of 11.36%. Progyny's revenue was up 2.0% on a year-over-year basis. During the same quarter last year, the firm posted $0.16 earnings per share. On average, equities analysts forecast that Progyny, Inc. will post 0.56 EPS for the current year.

About Progyny

Progyny, Inc, a benefits management company, specializes in fertility and family building benefits solutions in the United States. Its fertility benefits solution includes differentiated benefits plan design, personalized concierge-style member support services, and selective network of fertility specialists.